We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test Accurately Diagnoses Early-Stage Osteoarthritis

By LabMedica International staff writers
Posted on 31 Oct 2022

Researchers have developed a blood test for diagnosis of early-stage osteoarthritis. More...

This breakthrough is especially important because early detection of arthritis enables treatment and support to be given before irreversible damage to the joints has occurred. In addition, the test identifies the type of arthritis, giving physicians an advantage on the appropriate type of treatment. This will provide both individual and societal benefit in maintaining a healthy, independent and functional workforce.

The blood test developed by researchers at Qatar University (Doha, Qatar) in collaboration with the University of Warwick (Coventry, UK) quantifies modified amino acids released from proteins in the joints into the blood during the early stages of development of arthritis. The amount and pattern of these compounds is characteristic for arthritis and, more specifically, the kind of arthritis – osteoarthritis, rheumatoid arthritis or other inflammatory joint disease which often heals itself.

Using machine-learning analysis, the researchers developed diagnostic algorithms based on levels and combinations of these modified amino acids that could distinguish if arthritis was or was not present, and then algorithms that could distinguish between early-stage osteoarthritis, early rheumatoid arthritis, and other self-resolving inflammatory joint disease. The blood test has high accuracy (92%), sensitivity (92%) and specificity (90%). The researchers have further validated the blood test diagnostic algorithm in over 350 samples. The test may also find use in monitoring the effectiveness of treatments and also post-operative recovery after joint replacement surgery.

“Currently there is no test for early-stage diagnosis of osteoarthritis and the test for early-stage rheumatoid arthritis needs improvement. Our test solves both of these problems,” said Dr. Naila Rabbani, lead author of the study and Professor of Basic Medical Sciences at Qatar University. “The test is based on quantifying fragments of damaged protein produced in early-stage arthritis that leak from the joint into blood. It is based on markers of the disease mechanism and hence achieves great accuracy.”

“Use of the test will help guide physicians at the earliest stage at which their patient experiences joint pain as to whether arthritis is present or not. Acting on the outcome of this test, the physicians will enable appropriate therapy to be initiated at an early stage when there is a good chance to avoid development to severe disease,” added Dr. Rabbani.

Related Links:
Qatar University 
University of Warwick 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.